Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.